Your New Approach to acne is here. See Results.

In a clinical trial, patients using AKLIEF® (trifarotene) Cream, 0.005% achieved RAPID RESULTS* ON THE FACE, CHEST, SHOULDERS, AND BACK.

Study 18251: Double-blind, randomized, vehicle-controlled safety and efficacy 12-week trial of trifarotene cream vs vehicle cream.
Subject: 8511-004 | Age: 16 | Gender: Female

Study 118295: Open-label, single-arm study of trifarotene cream for 24 weeks.
Subject: 8447-004 | Age: 16 | Gender: Male

Study 18251: Double-blind, randomized, vehicle-controlled safety and efficacy 12-week trial of trifarotene cream vs vehicle cream.
Subject: 8511-004 | Age: 16 | Gender: Female

Study 118295: Open-label, single-arm study of trifarotene cream for 24 weeks.
Subject: 8240-010 | Age: 14 | Gender: Male

Image

If eligible, you may be able to save.

GET SAVINGS
Image

Find quick answers to your questions.

GO TO FAQs
Image

Tips for Talking with your dermatology provider.

GET YOUR GUIDE

*Indicating a 2-week time frame for results on the face; a 4-week time frame for results on the body.1

Galderma CareConnect Patient Savings Program is only available for commercially insured or uninsured patients. Patients who are enrolled in a government-run or government sponsored healthcare plan with a pharmacy benefit are not eligible to use the Galderma CareConnect patient savings card.

Reference: 1. Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 µg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691-1699.

IMPORTANT SAFETY INFORMATION

Indication: AKLIEF® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Warnings/Precautions: Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. Avoid application of AKLIEF Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Indication: AKLIEF® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Please see complete Important Safety Information below.

Scroll to ISI